Glycaemic control, disease duration and β-cell function in patients with Type 2 diabetes in a Swedish community. Skaraborg Hypertension and Diabetes Project

Diabetic Medicine

Volumn 19, Issue 2, 2002, Pages 125-129

  Ostgren C J ^a,b   Lindblad, U ^a,c   Ranstam, J ^d   Melander, A ^a,e   Rastam L ^a,f  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Odeshog Health Care Centre   (Sweden)

^c Skaraborgs Institutet   (Sweden)

^d MALMÖ UNIVERSITY   (Sweden)

^e Network for Pharmacoepidemiology Foundation   (Sweden)

^f SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Glucose toxicity; Primary care; Serum insulin

Indexed keywords

HEMOGLOBIN A1C; INSULIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD GLUCOSE MONITORING; BODY SIZE; CARDIOVASCULAR RISK; COMMUNITY CARE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HEMOGLOBIN DETERMINATION; HOMEOSTASIS; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LINEAR REGRESSION ANALYSIS; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY MEDICAL CARE; RISK FACTOR; SWEDEN; TRIACYLGLYCEROL BLOOD LEVEL;

AGE OF ONSET; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; ISLETS OF LANGERHANS; MALE; RISK FACTORS; SWEDEN; TRIGLYCERIDES;

EID: 0036125347     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2002.00661.x     Document Type: Article

References (27)

1. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians
2. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: Results of a 25-year follow-up study
3. Role of insulin resistance in human disease. Banting Lecture 1988
4. Impaired glucose tolerant subjects exhibit a beta-cell defect despite normal fasting glycemia
5. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies
6. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease
7. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: The 10-year follow-up of the Belfast Diet study
8. Risk factor clustering in patients with hypertension and NIDDM
9. The Skaraborg Project - A controlled trial regarding the effect of structured hypertension care
10. The Skaraborg Hypertension Project 3. Influence on blood pressure of a medical care program for hypertension
11. Reduced stroke incidence with structured hypertension care: The Skaraborg Hypertension Project
12. Control of blood pressure and risk of myocardial infarction: Skaraborg Hypertension Project
13. Improved method for analysis of glycated haemoglobin by ion exchange chromatography
14. Enzyme immunoassay for intact human insulin in serum or plasma
15. A desktop guide to Type 2 diabetes mellitus
16. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man
17. The homeostasis model in the San Antonio Heart study
18. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus (1)
19. Glucose toxicity
20. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study
21. Differences in treatment and metabolic abnormalities between normo- and hypertensive patients with type 2 diabetes
22. Glycemic control and cardiovascular risk factors in type 2 diabetes: A population-based study
23. Weight and non-insulin-dependent diabetes mellitus
24. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes
25. Weight gain as a risk factor for clinical diabetes mellitus in women
26. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus
27. Decreased insulin action and insulin secretion predict the development of impaired glucose tolerance